British vaccine maker Acambis announced the departure of its chief executive and chief financial officer, and said on Wednesday it planned to cut its cost base by 20 percent, including about 40 job losses.
The firm, hit hard when it was dropped by the U.S. government from consideration for a new smallpox vaccine tender, said Ian Garland, the former chief financial officer of Arrow Therapeutics (recently bought by AstraZeneca), would become chief executive from June 1.
He will replace Gordon Cameron as CEO.
Chief Financial Officer (CFO) David Lawrence will leave with immediate effect and be replaced by Elizabeth Brown as acting CFO.
More
No comments:
Post a Comment